Putting the STING into cancer immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
Gene-editing technique could speed up study of cancer mutations
With the new method, scientists can explore many cancer mutations whose roles are unknown, helping them develop new drugs that target those mutations.
A simple paper test could offer early cancer diagnosis
The new diagnostic, which is based on analysis of urine samples, could also be designed to reveal whether a tumor has metastasized.
Nanoparticles provoke immune response against tumors but avoid side effects
In a new study, immunostimulatory drugs slowed tumor growth without producing systemic inflammation.
Study: Shutting down nuclear power could increase air pollution
If reactors are retired, polluting energy sources that fill the gap could cause more than 5,000 premature deaths, researchers estimate.
A shot in the arm
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics.
A new control switch could make RNA therapies easier to program
Using this approach, researchers hope to deliver therapeutic RNA molecules selectively to cancer cells or other target cells.
A traveler on bioengineering’s many paths
Immunology research, public health service, and student leadership are all part of senior Julian Zulueta’s journey toward becoming a physician-scientist.
Why lung cancer doesn’t respond well to immunotherapy
A new study reveals that lymph nodes near the lungs create an environment that weakens T-cell responses to tumors.
Targeting cancer with a multidrug nanoparticle
Using bottlebrush-shaped particles, researchers can identify and deliver synergistic combinations of cancer drugs.
MIT researchers develop an AI model that can detect future lung cancer risk
Deep-learning model takes a personalized approach to assessing each patient’s risk of lung cancer based on CT scans.
Compassion in the details
The late MIT Professor Angelika Amon was recognized as Committed to Caring for her generous and encompassing mentorship.
Enzyme “atlas” helps researchers decipher cellular pathways
Biologists have mapped out more than 300 protein kinases and their targets, which they hope could yield new leads for cancer drugs.
New tool can assist with identifying carbohydrate-binding proteins
Groundbreaking research can help alleviate the challenges affiliated with studying carbohydrates.
Honoring Salvador Luria, longtime MIT professor and founding director of the MIT Center for Cancer Research
Koch Institute event celebrates the new MIT Press biography “Salvador Luria: An Immigrant Biologist in Cold War America.”